Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.36 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23848610 | 0.94 | KMT2A (0.50) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL25501955 | 0.92 | POLB (0.41) | KMT2AFKBP1AGLAPOLBMOGAT2 | |
| SCHEMBL25502166 | 0.92 | FKBP1A (0.42) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL23848476 | 0.89 | KMT2A (0.45) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL23832805 | 0.89 | KMT2A (0.45) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL23832785 | 0.88 | KMT2A (0.42) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL30096698 | 0.88 | KMT2A (0.42) | KMT2AFKBP1AGLAPOLBMGAT2 | |
| SCHEMBL25502088 | 0.87 | KMT2A (0.40) | KMT2AFKBP1AGLAMGAT2MOGAT2 | |
| SCHEMBL23848206 | 0.87 | KMT2A (0.41) | KMT2AFKBP1AGLAMEN1PKM | |
| SCHEMBL23832787 | 0.87 | FKBP1A (0.43) | KMT2AFKBP1AGLAPOLBMGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | ATUX ISKAY LLC | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146127-A1 | 3-DIARYLMETHYLENES AND USES THEREOF | MYC, MYCBP, FOXO1 | KMT2A 742/4885FKBP1A 1315/4885GLA 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.